Amarin Corp Plc (AMRN)

[HDGabor]

Just rewording the BD ...

1. Please discuss the efficacy results from the ANCHOR trial, including the clinical significance of the observed changes in lipid/lipoprotein parameters and your level of confidence that these changes will translate into a meaningful reduction in TG among the target population with CV risk.
2. Taking into account the described efficacy and safety data for Vascepa, do you believe that its effects on the described lipid/lipoprotein parameters are NOT sufficient to grant approval for co-administration with statin therapy for the treatment of
patients with mixed dyslipidemia and CHD or CHD risk equivalent prior to the completion of REDUCE-IT? Please provide the rationale underlying your recommendation.